↓ Skip to main content

Lenalidomide is safe and active in Waldenström macroglobulinemia

Overview of attention for article published in American Journal of Hematology, October 2015

About this Attention Score

  • Good Attention Score compared to outputs of the same age (74th percentile)
  • Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter
4 X users
patent
1 patent

Readers on

mendeley
43 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Lenalidomide is safe and active in Waldenström macroglobulinemia
Published in
American Journal of Hematology, October 2015
DOI 10.1002/ajh.24175
Pubmed ID
Authors
Abstract

Lenalidomide is manageable and effective in Multiple Myeloma, particularly in elderly patients. Surprisingly, the combination of lenalidomide with rituximab produced clinically significant anemia at 25mg/day for 21/28 days, the highest possible dose, in Waldenström's Macroglobulinemia (WM). We aimed to determine the maximum tolerated dose (MTD) of single agent lenalidomide and determine its impact on WM. RV-WM-0426 is a multicenter dose escalation open label phase 1/2 study of lenalidomide in relapsed/refractory WM (RRWM). Lenalidomide was given orally 21/28 days per cycle for one year, at escalated dose of 15 to 20 mg during phase 1 to determine the MTD; the phase 2 part was conducted at the MTD. 17 RRWM patients were included. The MTD was established at 15 mg/day 21/28. By ITT analysis, the overall response rate was 29%. With a median follow-up of 36 months, median TTP was 16 months (95%CI 5.5-26), the 5-year OS was 91%. The most frequent AE ≥ grade 3 at 15mg were 14% anemia and 43% neutropenia. The MTD of lenalidomide is 15mg/day 21/28 days in RRWM. Lenalidomide is active in the treatment of RRWM and the safety profile appears manageable. Future studies may look into combinations of lenalidomide and continuous dosing. This article is protected by copyright. All rights reserved.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
United States 1 2%
United Kingdom 1 2%
Unknown 41 95%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Master 5 12%
Researcher 4 9%
Other 3 7%
Student > Bachelor 3 7%
Lecturer 2 5%
Other 9 21%
Unknown 17 40%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 12 28%
Biochemistry, Genetics and Molecular Biology 3 7%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Agricultural and Biological Sciences 2 5%
Immunology and Microbiology 2 5%
Other 4 9%
Unknown 18 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2018.
All research outputs
#7,904,121
of 30,598,342 outputs
Outputs from American Journal of Hematology
#1,709
of 4,660 outputs
Outputs of similar age
#76,383
of 299,036 outputs
Outputs of similar age from American Journal of Hematology
#13
of 50 outputs
Altmetric has tracked 30,598,342 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 4,660 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 10.0. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 299,036 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.